EMA Authorised: Xbonzy (denosumab) — Reddy Holding GmbH

View source ↗

Summary

The EMA authorised Xbonzy (denosumab) by Reddy Holding GmbH for the treatment of giant cell tumor of bone and other bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Xbonzy (denosumab)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Reddy Holding GmbH. Decision date: 08/01/2026